Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe Allows Derogation of Atypical Actives from ICH Q7

This article was originally published in The Gold Sheet

Executive Summary

The European Medicines Agency tackled the issue of atypical actives in 2008, David Cockburn, head of manufacturing quality compliance at EMA, told a recent PDA workshop in Bethesda, Md.

You may also be interested in...



Threat of Sanctions, Shortages, Spurs Talk of Standards for Atypical Actives

As the pharmaceutical supply chain comes under increased regulatory scrutiny, FDA inspectors are finding manufacturers using excipients as active ingredients, even though they don’t meet active ingredient standards, and the industry is talking about establishing a new set of standards for these so-called atypical actives, and perhaps coaxing FDA into ratifying them via guidance.

A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study

The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel